The Effectiveness of Low-Dose Colchicine in the Treatment of Steroid- Resistant Primary Focal Segmental Glomerulosclerosis | ||
| Benha Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 17 October 2025 PDF (677.42 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2025.405093.2553 | ||
| Authors | ||
| El-Metwaly L. El Shahawy1; Mohamed E. Ebrahim1; Ahmed E. Mansour2; Shaimaa M. Mohamed3; Hanan K. Abdelkader* 4 | ||
| 1Professor of Internal Medicine and Nephrology, Faculty of Medicine, Benha University | ||
| 2Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine, Benha University | ||
| 3Lecturer of Internal Medicine and Nephrology, Faculty of Medicine, Benha University | ||
| 4M.B.B.Ch, Faculty of Medicine, Benha University | ||
| Abstract | ||
| Background: Focal Segmental Glomerulosclerosis (FSGS) is an uncommon disease that is found only in 9% of all kidney biopsies. with stable rates in recent years. This study aimed to investigate the effect of low dose colchicine (LODOCO) (0.5mg once daily) as Add-On therapy on the response and progression of steroid resistant primary FSGS in patients receiving standard care. Methods: The study was carried on 40 patients with primary FSGS resistant to corticosteroids admitted to Nephrology Department at Benha University Hospitals. Results: The eGFR was significantly increased during follow-up (P<0.001). The eGFR was significantly higher at 1, 2 and 3 months compared to baseline (P<0.001, <0.001, <0.001), was significantly at 2 and 3 months compared to 1 month (P <0.001, <0.001) and was significantly higher at 3 months compared to 2 months (P <0.001). The response to LODOCO after 3 months, 22 (55%) patients showed complete remission whereas 18 (45%) patients showed partial remission. Conclusion: LODOCO (0.5 mg once daily) is promising therapy for steroid resistant FSGS with 55% with complete remission whereas 45% with partial remission. In patients with focal segmental glomerulosclerosis resistant to corticosteroid receiving low dose colchicine (0.5 mg once daily) as Add-On drug for 3 months explore promise improving both estimated glomerular filtration rate and albuminuria, 55% with complete remission and 45% with partial remission. Achieving remission of proteinuria is crucial for slowing disease progression. | ||
| Keywords | ||
| Low-Dose Colchicine; Primary Focal Segmental Glomerulosclerosis; Steroid-Sensitive, Estimated Glomerular Filtration | ||
|
Statistics Article View: 5 PDF Download: 6 |
||
